Introduction {#Sec1}
============

In previously studies, we isolated ingenol compounds from *Euphorbia kansui* that inhibited topoisomerase (topo) activity and/or the proliferative activity of cancer cells (Wang et al. [@CR32]; Miyata et al. [@CR18]). DNA topo I and II relax helical supercoiling generated during transcription, replication, and chromatin remodeling (Wang [@CR31]). Topo I transiently cleaves a single strand of DNA, whereas topo II cleaves double-stranded DNA (Burden and Osheroff [@CR6]; Pommier [@CR21]). The anti-cancer drugs camptothecin (CPT) and etoposide belong to the family of topo I and topo II inhibitors, respectively. The mechanisms of the catalytic cycle of topo I has been described as a controlled rotation process as follows: (a) topo I binds to the DNA substrate to form a topo I--DNA noncovalent complex; (b) topo I catalyzes the cleavage of one DNA strand to form a transient topo I cleavable complex; (c) controlled rotation releases the superhelical tension of DNA; (d) the cleaved DNA strand is religated; and (e) topo I is released from the relaxed DNA and undergoes another cycle of DNA relaxation (Champoux [@CR8]). DNA topo I and II can be inhibited through different mechanisms by two classes of agents: class I (poisons) and class II (catalytic inhibitors) (Burden and Osheroff [@CR6]; Andoh and Ishida [@CR1]; Bailly [@CR3]; Capranico et al. [@CR7]; Wu et al. [@CR34]). Class I inhibitors stabilize the DNA cleavable complex and block the subsequent rejoining of DNA breaks. When advancing replication forks collide with the drug-stabilized topo I--DNA cleavable complexes, DNA double strand breaks (DSBs) are formed (Pommier [@CR21]). In a subsequent reaction, these DSBs induce a DNA damage checkpoint response through ATM/ATR activation and subsequent H2AX phosphorylation (Burden and Osheroff [@CR6]; Cliby et al. [@CR10]; Furuta et al. [@CR12]; Pommier et al. [@CR22]). Class II catalytic inhibitors act by inhibiting any other step of the topo-I and II enzymatic cycle and induce a decatenation checkpoint response by ATR activation (Deming et al. [@CR11]) and subsequent G2/M arrest (Deming et al. [@CR11]; Wu et al. [@CR34]).

Within the set of topo II inhibitors investigated (Miyata et al. [@CR18]) we found inhibitory activity of topo I in vitro by 3EZ20Ac-ingenol (Fig. [1](#Fig1){ref-type="fig"}). The present work describes experiments designed to identify mechanisms of inhibition of 3EZ,20Ac-ingenol against topo I. CPT and water-soluble derivatives of CPT are presently the most potent and poisonous (class I) topo I inhibitors. To determine whether the mode of inhibition of topo I activity by 3EZ,20Ac-ingenol is similar to that by the CPT analogue, 10-hydroxycamptothecin (hCPT), we analyzed the ability of 3EZ,20Ac-ingenol to introduce single-strand DNA breaks using plasmid DNA. In contrast to hCPT, 3EZ,20Ac-ingenol could not generate cleavable complexes, inhibit the endonuclease activity of topo I, and display characteristics of catalytic inhibitors (class II). Although, the topo I poison drugs CPT and topotecan and the topo II poison drugs adriamycin and etoposide stabilize the covalent topo--DNA cleavable complexes, thereby inducing DSBs, the topo I catalytic inhibitorβ-lapachone, the topo II catalytic inhibitor ICRF-193 and a dual catalytic inhibitor of topo I and II F 11782 do not induce DSBs (Burden and Osheroff [@CR6]; Andoh and Ishida [@CR1]; Capranico et al. [@CR7]). However, we reported that although 20-*O*-ingenolEZ inhibits the ATPase activity of topo II and induces G2 arrest by inhibiting DNA decatenation in mouse mammary tumor (MMT) cells, it induces DSBs and apoptosis in BLM^−/−^ DT40 cells (Watanabe et al. [@CR33]). Recent studies have suggested that catalytic topo II inhibitor ICRF-193 induces DSBs by acting as topo II poisons (Park and Avraham [@CR20]; Robinson et al. [@CR25]). In this study, using wild-type and repair-related gene-muted DT40 cells, we analyzed whether the dual catalytic inhibitor of topo 1 and II 3EZ,20Ac-ingenol from *Euphorbia* (Fig. [1](#Fig1){ref-type="fig"}) induces DNA DSBs. Phosphorylated H2AX (γH2AX), a DNA damage marker that can be used as a clinical marker of the efficacy of cancer drugs (Antony et al. [@CR2]; Teicher [@CR30]), was detectable at pharmacologically relevant levels in DT40 cells treated with 3EZ,20Ac-ingenol. We found that although 3EZ,20Ac-ingenol did not stabilize topo I--DNA-cleavable complexes, it induced downregulation of Akt, DSBs and apoptosis in DT40 cells.Fig. 1Structure of the diterpene compound, 3-*O*-(2′E,4′Z-decadienoyl)-20-*O*-acetylingenol (3EZ,20Ac-ingenol)

Materials and methods {#Sec2}
=====================

Cell lines and cell proliferation {#Sec3}
---------------------------------

BLM^−/−^ and WRN^−/−^ DT40 cells and wild-type DT40 cells were provided by the RIKEN BRC through the National Bio-Resource Project of the MEXT, Japan. The diterpene compound, 3-*O*-(2′E,4′Z-decadienoyl)-20-*O*-acetylingenol (3EZ,20Ac-ingenol) (Fig. [1](#Fig1){ref-type="fig"}) was dissolved in dimethyl sulfoxide. BLM^−/−^ and WRN^−/−^ DT40 cells and DT40 cells were incubated in RPMI 1640 supplemented for 24 h at 37 °C as described previously (Watanabe et al. [@CR33]). Cell growth was determined by the 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyl-tetrazolium bromide (MTT) assay using the Cell Proliferation Kit I (Roche Applied Science). The optical density of each well was measured at 620 nm using a plate reader (Amersham).

Cell cycle analysis {#Sec4}
-------------------

DT40 cells were treated with 0.5 μM 3EZ,20Ac-ingenol for 0, 6, 12, 24 and 48 h or were treated with 0.01, 0.1 and 1 μM 3EZ,20Ac-ingenol for 24 h. The cells were then harvested and fixed with 70 % ethanol for 24 h. After centrifugation at 3,000 rpm for 5 min, the cell pellets were washed with phosphate-buffered saline (PBS) and resuspended in PBS containing propidium iodide (50 μg/ml) and DNase-free RNase (50 μg/ml). The cells were then incubated at 37 °C for 20 min, and the DNA content was determined by flow cytometry (Beckman Coulter).

pBR322 DNA plasmid relaxation assay {#Sec5}
-----------------------------------

The effects of the compounds on relaxation by DNA topo I (human recombinant in *E. coli* TopGEN) were determined by measuring the conversion of supercoiled pBR 322 plasmid DNA to its relaxed form. The reaction mixture contained 20 mM Tris--HCl (pH 7.9), 100 mM KCl, 10 mM MgCl~2~, 0.1 mM EDTA, 50 μg/ml BSA, 100 ng pBR 322 DNA, 0.16 U of enzyme, and different concentrations of the drugs in a total volume of 20 μl. After incubation for 15 min at 37 °C, the mixtures were subjected to electrophoresis on a 1 % agarose gel. After electrophoresis, the gels were stained with ethidium bromide and photographed under UV light.

pBR322 plasmid DNA cleavage assay {#Sec6}
---------------------------------

Topo I-mediated DNA cleavage assays were performed as described previously (Raspaglio et al. [@CR24]). Plasmid DNA (10 ng) was incubated in a solution (20 μl) containing 20 mM Tris--HCl (pH 7.9), 10 mM MgCl~2~, 0.1 mM KCl, 0.1 mM EDTA, 50 μg/ml BSA, 2 U of topo I, and drugs. Reactions were initiated by the addition of DNA and incubated at 100 °C for 3 min. After digestion with proteinase K, open circular and linear DNA were separated from intact supercoiled and relaxed DNA by agarose gel electrophoresis in the presence of 1 μg/ml ethidium bromide. After electrophoresis at 4 °C, the gels were photographed under UV light.

Analysis of topo I/DNA binding by electrophoretic mobility shift assay (EMSA) {#Sec7}
-----------------------------------------------------------------------------

EMSAs were performed as described previously (Boege et al. [@CR5]). In total, 7.2 U of topo I protein was added to the reaction mixture containing 150 ng of plasmid DNA and 500 μM of 3EZ,20Ac-ingenol or 40 μM of hCPT. The assays were performed in the reaction mixture (10 mM Tris--HCl (pH7.9), 10 mM MgCl~2~, 10 mM KCl, 0.1 mM DTT, and 10 % dimethyl sulfoxide). The reaction products were immediately analyzed by electrophoresis on a 1 % agarose gel.

3EZ,20Ac-ingenol--DNA intercalation {#Sec8}
-----------------------------------

The reaction buffer containing 20 mM Tris--HCl (pH 7.9), 100 mM KCl, 10 mM MgCl~2~, 0.1 mM EDTA, 50 μg/ml BSA, 150 μg of plasmid pBR322 DNA and 0.16 U of topo1 (Topo GEN) was preincubated at 37 °C for 15 min (Pommier et al. [@CR23]). Assays were performed in the reaction buffer in the presence of 25 μM 3EZ,20Ac-ingenol or 25 μM adriamycin at 37 °C for 60 min. The reactions were halted by the addition of stop solution and electrophoresed on 1 % agarose gel.

Immunoblotting {#Sec9}
--------------

DT40 cells were cultured for various time periods in the presence of 0.5 μM 3EZ,20Ac-ingenol and washed in PBS. The cells were solubilized using cytoplasmic extraction reagents (Thermo Scientific). The protein concentrations were determined using the Bradford reagent for protein assays (Bio-Rad Laboratories), and 30 μg of the cell lysates was resolved on 15 % SDS polyacrylamide gels and transferred onto a polyvinylidene difluoride membrane. The blots were made using anti-p-Akt (Ser473) (Cell Signaling Technology), anti-γH2AX (Millipore), and anti-caspase 3 (R&D Systems) antibodies followed by detection using an enhanced chemiluminescence system.

Results {#Sec10}
=======

Effects of 3EZ,20Ac-ingenol on the proliferative activity of BLM^−/−^ and WRN^−/−^ DT40 cells and wild-type DT40 cells {#Sec11}
----------------------------------------------------------------------------------------------------------------------

To investigate the inhibitory effects of 3EZ,20Ac-ingenol on the proliferation of BLM^−/−^ and WRN^−/−^ DT40 cells and wild-type DT40 cells, a concentration-response range (0.1 and 10 μM) was established using an exposure time of 24 h (Fig. [2](#Fig2){ref-type="fig"}). The proliferation of WRN^−/−^ DT40 cells and DT40 cells was gradually inhibited as the concentration of 3EZ,20Ac-ingenol increased, reaching a maximum inhibition of \~50--70 % at 0.5 μM (Fig. [2](#Fig2){ref-type="fig"}). The proliferation of WRN^−/−^ DT40 cell and wild-type DT40 cells was more sensitive to 3EZ,20Ac-ingenol than that of BLM^−/−^ DT40 cells at restricted concentrations of 0.5 and 1 μM 3EZ,20Ac-ingenol. However, there were no difference in proliferation of BLM^−/−^ cells and wild-type DT40 cells or WRN^−/−^ DT40 cell and wild-type DT40 cells at other concentrations (0.1, 5 or 10 μM). There was no difference in the inhibition of proliferation for wild-type and repair-related gene-muted DT40 cells. The proliferation of other human cancer cells such as breast cancer MCF-7 and BT-474 cells or normal B lymphocytes (HEV0011) was not inhibited by 3EZ,20Ac-ingenol at concentrations of 0.1--10 μM and the inhibition of leukemia cell (BALL-1) proliferation was more sensitive (data not shown).Fig. 2Effects of 3EZ,20Ac-ingenol on the cell proliferative activity, WRN^−/−^ and BLM^−/−^ DT40 and DT 40 cells were cultured in microplates at 37 °C for 24 h in the absence or presence of 0.1, 0.5, 1, 5 and 10 μM 3EZ,20Ac-ingenol. Relative cell growth was determined by the MTT assay. The growth of untreated WRN^−/−^ and BLM^−/−^ DT40 and wild-type DT40 cells was set as 100 %, and the growth of treated WRN^−/−^ and BLM^−/−^ DT40 and DT40 cells was expressed relative to the growth of untreated cells. The expressions were performed in triplicate, and the data are shown as the mean ± standard deviation

Flow cytometric analysis {#Sec12}
------------------------

We determined the effects of 3EZ,20Ac-ingenol on cell cycle distributions by flow cytometry. We treated DT40 cells with 3EZ,20Ac-ingenol at 0.5 μM for 6, 12, 24 and 48 h and then performed cell cycle analysis by flow cytometry (Fig. [3](#Fig3){ref-type="fig"}a). The results revealed that the 3EZ,20Ac-ingenol-treated DT40 cells were arrested in the G2/M phase at 6 h. At 6 h, 21 % of the cell population was in the G2/M phase, with 20 and 18 % at 12 and 24 h, respectively (Fig. [3](#Fig3){ref-type="fig"}c), compared with 14 % in the untreated cells. In contrast, in the S phase, the population was decreased to 52 and 49 % after 6 and 12 h of treatment, respectively, compared with 59 % in the untreated cells. Apoptotic progress was slow with 3EZ,20Ac-ingenol treatment until 24 h, and 18 % of cells were detected in the sub-G1 phase (Fig. [3](#Fig3){ref-type="fig"}a). This population was largely predominant at 48 h, and \~73 % of the cells were in the sub-G1 phase (Fig. [3](#Fig3){ref-type="fig"}a). The cell cycle effects of 3EZ,20Ac-ingenol were also examined as a function of the drug concentration (Fig. [3](#Fig3){ref-type="fig"}b). G2/M phase arrest occurred at a relatively low concentration (27 % at 0.01 μM as compared with 13 % in the control) and increased drug concentrations caused an obvious decline from 27 % at 0.01 μM to 24 % at 0.1 μM, 16 % at 0.5 μM, and 7 % at 1 μM after 24 of treatment (Fig. [3](#Fig3){ref-type="fig"}c, d). In contrast, DT40 cells treated with 1 μM 3EZ,20Ac-ingenol had a higher proportion, in which up to 57 % of cells had sub-G1 DNA (Fig. [3](#Fig3){ref-type="fig"}b), indicating the commitment of these cells to apoptosis. We also treated DT40 cells with 0.5 μM 3EZ,20Ac-ingenol for various periods, and the DT40 cells were most arrested in the G2/M phase after 6 h (Fig. [3](#Fig3){ref-type="fig"}c). After the G2/M phase arrest, cell apoptosis may occur selectively in G2/M phase in the presence of 3EZ,20Ac-ingenol.Fig. 3Cell cycle analysis, DT40 cells were treated with 0.5 μM 3EZ,20Ac-ingenol for 0, 6, 12, 24 and 48 h (**a**) or were treated with 0.01, 0.1 and 1 μM 3EZ,20Ac-ingenol for 24 h (**b**). The cells were stained with propidium iodide and subjected to flow-cytometric analysis. **c**, **d** shows the results of **a**, **b** with the percent distribution, respectively

pBR322 plasmid DNA relaxation assay {#Sec13}
-----------------------------------

The topo I inhibitory activity of 3EZ,20Ac-ingenol was studied by the DNA relaxation assay. hCPT, a well-known topo I inhibitor, was used as a positive control. Inhibition of DNA relaxation by 3EZ,20Ac-ingenol was not observed at concentration less than 1 μM (Fig. [4](#Fig4){ref-type="fig"}a). 3EZ,20Ac-ingenol had slight inhibitory effects on DNA relaxation at 10 μM (Fig. [4](#Fig4){ref-type="fig"}a) and significantly inhibited DNA relaxation at 25 μM (Fig. [4](#Fig4){ref-type="fig"}a). hCPT also inhibited DNA relaxation to the same degree as 3EZ,20Ac-ingenol (Fig. [4](#Fig4){ref-type="fig"}b). We previously reported that the in vitro inhibition of topo by 3EZ,20Ac-ingenol was caused by topo II catalytic inhibition (Miyata et al. [@CR18]). Thus, 3EZ,20Ac-ingenol inhibited topo I and II activity in vitro.Fig. 4Inhibition of topo I activity by 3EZ,20Ac-ingenol and the mechanism of action. **a** Inhibition of pBR322 DNA relaxation by 3EZ,20Ac-ingenol, *N* DNA only, *C* DNA plus enzyme. **b** Inhibition of pBR322 relaxation by hCPT, *N* DNA only, *C* DNA plus enzyme. **c** The effect of 3EZ,20Ac-ingenol and hCPT on the formation of DNA-enzyme cleavable complexes, *N* DNA only, *C* DNA plus enzyme. **d** Inhibition of hCPT-induced topo I-mediated DNA cleavable complex formation by 3EZ,20Ac-ingenol. **e** Electrophoretic mobility shift assay (EMSA) to study the effect of 3EZ,20Ac-ingenol on the binding of topo I to DAN, *N* DNA only, *C* DNA plus enzyme. **f** DNA intercalation assay, *N* DNA only, *C* DNA plus enzyme. *R* relaxed DNA, *S* supercoiled DNA, *C* DNA cleavage, *PB* protein-bound DNA, *ADM* adriamycin

pBR322 plasmid DNA cleavage assay {#Sec14}
---------------------------------

Topo I poisons such as CPT inhibit religase by affecting the cleavage step. CPT entraps a migration complex known as the cleavable complex, which is formed by the enzyme, drug, and DNA. Thus, we tested whether 3EZ,20Ac-ingenol also induced the formation of cleavable complexes similar to hCPT-like compounds. This complex can be converted irreversibly into topo-linked DNA single-strand breaks after the addition of a strong protein denaturant (Raspaglio et al. [@CR24]). As shown in Fig. [4](#Fig4){ref-type="fig"}c, the induction of topo I-mediated DNA cleavage was detected when the concentration of hCPT was 10 or 20 μM. In contrast to hCPT, 3EZ,20Ac-ingenol had no effect on topo I-mediated DNA cleavage even at concentration as high as 200 μM (Fig. [4](#Fig4){ref-type="fig"}c).

Inhibition of hCPT-induced DNA cleavage by 3EZ,20Ac-ingenol {#Sec15}
-----------------------------------------------------------

Because 3EZ,20Ac-ingenol had no effect on the formation of cleavable complexes, the results indicated that the inhibition of topo I by 3EZ,20Ac-ingenol occurs upstream of the endonuclease activity of topo I and downstream of religation. Because hCPT inhibits the religation of cleaved DNA, if the interaction between DNA and topo I or the cleavage of one DNA strand to form the transient topo I cleavable complex before religation is blocked by 3EZ,20Ac-ingenol, the inhibition of hCPT-induced DNA cleavage by 3EZ,20Ac-ingenol would possible occur (Li et al. [@CR16]). Addition of 3EZ,20Ac-ingenol to the reaction buffer affected the cleavage of DNA by hCPT (Fig. [4](#Fig4){ref-type="fig"}d). Pretreatment with 3EZ,20Ac-ingenol at 100 μM abrogated the formation of this DNA cleavable complex by hCPT, which can be explained by inhibition of the interaction between DNA and topo I or cleavage of one DNA strand in the presence of 3EZ,20Ac-ingenol (Fig. [4](#Fig4){ref-type="fig"}d, lane 4). DNA was cleaved by topo I in the presence of hCPT (Fig. [4](#Fig4){ref-type="fig"}d, lane 5).

Binding analysis by EMSA {#Sec16}
------------------------

We showed that 3EZ,20Ac-ingenol pretreatment inhibited the formation of the cleavable complex stabilized by hCPT. Thus, we used the mobility shift assay to test whether 3EZ,20Ac-ingenol inhibited enzyme binding to DNA, which assembles a noncovalent enzyme--DNA complex, (Li et al. [@CR16]; Raspaglio et al. [@CR24]). The results shown in Fig. [4](#Fig4){ref-type="fig"}e, PB (lanes 2 and 3 compared with lane 1) illustrate the mobility of DNA in the presence of topo I, which is the result of a complex formed between the enzyme and DNA. Gel retardation was observed after the addition of 3EZ,20Ac-ingenol, indicating that 3EZ,20Ac-ingenol does not block the assembly of the noncovalent enzyme--DNA complex (Fig. [4](#Fig4){ref-type="fig"}e, PB, lanes 2 and 3). hCPT did not modulate the formation of the topo I--DNA complex (Fig. [4](#Fig4){ref-type="fig"}e, PB, lane 4). These results showed that 3EZ,20Ac-ingenol appears to inhibit the cleavage of one DNA strand in an earlier event of topo I-mediated DNA cleavable complex formation.

3EZ,20Ac-ingenol intercalation with DNA {#Sec17}
---------------------------------------

Many chemical compounds are known to affect the gross structure of DNA by intercalation and/or binding, which can affect the catalytic activity of topo I. We tested the ability of 3EZ,20Ac-ingenol to intercalate with DNA using a topo I-catalyzed unwinding assay based on the ability of intercalating compounds to unwind the DNA duplex and change the DNA twist (Raspaglio et al. [@CR24]). Supercoiling of the relaxed substrate DNA was induced in the presence of an intercalative drug such as adriamycin (Fig. [4](#Fig4){ref-type="fig"}f, lane 4). In contrast, supercoiling was not observed with 3EZ,20Ac-ingenol (Fig. [4](#Fig4){ref-type="fig"}f, lane 3).

Influence of 3EZ,20Ac-ingenol on the PI3K/Akt pathway in DT40 cells {#Sec18}
-------------------------------------------------------------------

PI3K/Akt activity has been demonstrated to be regulated by genotoxins, and it plays important roles in cell apoptosis (Roos and Kaina [@CR27]; Xu et al. [@CR36]). The inhibition of p-Akt was observed in DT40 cells treated with 0.5 μM 3EZ,20Ac-ingenol, 8 h after 3EZ,20Ac-ingenol treatment, whereas the expression level of total Akt protein experienced little or no change (Fig. [5](#Fig5){ref-type="fig"}a). The inhibition of p-Akt in hCPT-treated cells was also observed after 4--8 h, which was almost simultaneous with the downregulation of p-Akt in 3EZ,20Ac-ingenol treated DT40 cells (Fig. [5](#Fig5){ref-type="fig"}a).Fig. 5Analysis of p-Akt content, phosphorylated H2AX (γH2AX) formation, and caspase 3 activation by immunoblotting. **a** Influence of 3EZ,20Ac-ingenol on p-Akt protein expression. **b** Influence of 3EZ,20Ac-ingenol on H2AX phosphorylation. **c** Influence of 3EZ,20Ac-ingenol on caspase 3 activation. **a**--**c** (*left*) DT40 cells were treated with 0.01, 0.1, 0.5 and 1 μM 3EZ,20Ac-ingenol for 24 h; (*center*) DT40 cells were treated with 0.5 μM 3EZ,20Ac-ingenol for 2, 4, 8, 12, and 24 h; and (*right*) DT40 cells were treated with 0.5 μM hCPT for 2, 4, 8, 12, and 24 h

Influence of 3EZ,20Ac-ingenol on H2AX phosphorylation in DT40 cells {#Sec19}
-------------------------------------------------------------------

γH2AX which serves as a marker of DNA DSBs, was visualized as a band stained with anti-γH2AX in DT 40 cells treated with 0.5 μM of 3EZ,20Ac-ingenol (Fig. [5](#Fig5){ref-type="fig"}b). Time-course analysis revealed H2AX phosphorylation after 12--24 h of 3EZ,20Ac-ingenol treatment. γH2AX was observed in hCPT treated cells after 2--4 h, revealing the extremely early appearance of γH2AX compared with H2AX phosphorylation in 3EZ,20Ac-ingenol treated cells (Fig. [5](#Fig5){ref-type="fig"}b).

Influence of 3EZ,20Ac-ingenol on caspase 3 activation {#Sec20}
-----------------------------------------------------

3EZ,20Ac-ingenol-treatment activated caspase 3 in DT40 cells in a concentration-dependent manner. Caspase 3 activation was observed in response to 0.5 μM of 3EZ,20Ac-ingenol and after 24 h at the same concentration (Fig. [5](#Fig5){ref-type="fig"}c). In contrast to the 3EZ,20Ac-ingenol treated cells, caspase 3 activation in hCPT-treated cells occurred after 4 h (Fig. [5](#Fig5){ref-type="fig"}c), which was slightly late than theγH2AX formation in hCPT treated cells (Fig. [5](#Fig5){ref-type="fig"}b).

Discussion {#Sec21}
==========

In this study, we observed that 3EZ,20Ac-ingenol interacted with topo I--DNA complexes and inhibited topo I-mediated DNA cleavage. It was previously shown 3EZ,20Ac-ingenol was a topo II catalytic inhibitor (Miyata et al. [@CR18]). Therefore, 3EZ,20Ac-ingenol inhibits both topo I and II activity in vitro. The catalytic topo inhibitor, 3EZ,20Ac-ingenol induced H2AX phosphorylation in response to agents that induce the formation of topo I-mediated DSBs in DT40 cells. Apoptosis was detected in 3EZ,20Ac-ingenol treated cells by γH2AX accumulation and caspase 3 activation during 12--24 h of treatment and through cell cycle analysis by flow cytometry between 24 and 48 h. To define the mechanisms of apoptosis induction, we studied whether 3EZ,20Ac-ingenol downregulated p-Akt (Ser 473) expression. We revealed that downregulation of p-Akt was initiated in DT40 cells after 8 h of treatment with 3EZ,20Ac-ingenol.

The formation of topo I-induced DNA DSBs can occur through two distinct mechanisms (Sordet et al. [@CR28]). The first type is topo I poison. These include clinically used drugs, for example, the prototypical topo I poison, CPT, which stabilizes topo I--DNA cleavable complexes and induces the accumulation of cleaved DNA, resulting in chromosomal damage (Pommier et al. [@CR22]). ATM/ATR is activated by DSBs formation and mediates subsequent H2AX phosphorylation and activation of checkpoint kinase, thereby inducing apoptosis via p53 (Cliby et al. [@CR10]; Furuta et al. [@CR12]; Roos and Kaina [@CR26]). The formation of DNA DSBs by topo I poisons can be detected by γH2AX during the initial 1 h of treatment (Furuta et al. [@CR12]). We also observed the appearance of γH2AX after 2 h of hCPT treatment.

Topo I and II poisons are commonly used as chemotherapeutic agents. However, topo I catalytic inhibitors that exhibit anti-tumor effects have also identified in cell culture (Yanagihara et al. [@CR37]; Bentle et al. [@CR4]; Ganguly et al. [@CR13]; Capranico et al. [@CR7]; Wu et al. [@CR34]). The second type topo induced DSBs are not formed directly and are related to endogenously produced reactive oxygen species (ROS) (Bentle et al. [@CR4]; Ganguly et al. [@CR13]; Kluza et al. [@CR15]). For example, betulinic acid (Ganguly et al. [@CR13]) binds with topo I, thereby precluding its interaction with substrate DNA (Chowdhury et al. [@CR9]). Events such as ROS generation and DNA fragmentation were observed in betulinic acid treated cells after 2--4 h, and ROS-induced apoptotic processes are the key steps in the blockade of cell cycle progression. β-lapachone (Li et al. [@CR16]; Bentle et al. [@CR4]) interacts with topo I rather than the DNA substrate and blocks the formation of cleavable complexes, however, it dose not induce the topo1-mediated DNA cleavage. β-lapachone induces the generation of NQO1-dependent ROS, DNA breaks, and γH2AX formation in the treated cells. γH2AX induced by ROS endogenously produced in response to the β-lapachone occurred during the initial 30--90 min of treatment (Bentle et al. [@CR4]).

It has been reported that ICRF-193, a catalytic topo II inhibitor, induces DSBs and apoptosis through activation of checkpoint kinas (Park and Avraham [@CR20]; Robinson et al. [@CR25]) or traps topo II into a circular clamp on DNA, which arrests transcription and triggers proteasomal degradation of topo II (Xiao et al. [@CR35]). However, the mechanism of induction of DSBs and apoptosis by topo I catalytic inhibitors remains unclear (Bentle et al. [@CR4]; Kluza et al. [@CR15]; Ganguly et al. [@CR13]; Capranico et al. [@CR7]). The mechanism for inducing DSBs and apoptosis of DT40 cells treated with the catalytic inhibitor 3EZ,20Ac-ingenol remains unknown. However, we consider that DNA damage derived from inhibiting DNA decatenation through the inhibition of topo I mediated DNA cleavage by 3EZ,20Ac-ingenol during the G2 phase is the key lesion. We previously reported the effects of the catalytic topo II inhibitor 20-*O*-ingenolEZ on the cell cycle distributions of MMT cells by flow cytometry (Yoshida et al. [@CR38]). At 12 h, 16.5 % of the cell population was in the G2/M phase. After 24 and 48 h of treatment, these values were 30 and 27 %, respectively, as compared with 12 % in untreated cells. MMT cells treated with 20-*O*-ingenolEZ were arrested in G2/M phase, but were not induced in apoptosis, whereas DT40 cells treated with the inhibiter were induced to undergo apoptosis (Yoshida et al. [@CR38]; Watanabe et al. [@CR33]). In this study, DT40 cells treated with the dual catalytic inhibitor of topo I and II 3EZ,20Ac-ingenol were also selectively arrested in G2/M phase and were induced to undergo apoptosis through signaling by cell cycle checkpoints in G2/M phase. Because DT40 cell lines do not express p53 (Takao et al. [@CR29]), they are arrested in G2/M phase by catalytic topo I and/or II inhibitory activity of 3EZ,20Ac-ingenol and may be induced to undergo apoptosis through p53-independent decatenation checkpoint pathway (Deming et al. [@CR11]; Roos and Kaina [@CR26]).

Genotoxins inhibit the Akt pathway in response to DNA damage, and they overcome the suppression of apoptosis by Akt to activate apoptosis effectively (Roos and Kaina [@CR27]; Xu et al. [@CR36]). The downregulation of p-Akt (Ser 473) is observed between 12 and 24 h of treatment by topotecan or SN-38 (Nakashio et al. [@CR19]; Liu et al. [@CR17]). The downregulation of p-Akt in betulinic acid-treated cells was also observed between 12 and 24 h of treatment and occurred after the ROS generation and DNA fragmentation (Ganguly et al. [@CR13]; Zhao et al. [@CR39]). Apoptosis is gradually induced at early time points, as indicated by DNA damage, and apoptotic evolution is strongly induced after 36 and 48 h of treatment, as observed by the downregulation of p-Akt (Nakashio et al. [@CR19]; Liu et al. [@CR17]; Zhao et al. [@CR39]). We showed that the downregulation of Akt in DT40 cells treated with hCPT was observed after 4 h and was almost the simultaneous with the appearance of DSBs and activation of caspase 3 in the treated DT40 cells. However, we demonstrated that the downregulation of p-Akt occurred in DT40 cells treated with 3EZ,20Ac-ingenol, and this downregulation was followed by the induction of H2AX phosphorylation and caspase 3 activation and subsequently followed by the intense induction of apoptosis through transition of cells to the sub-G1 phase between 24 and 48 h. Because p53 is frequently mutated in tumors (Hollstein et al. [@CR14]) and increased Akt kinase activity is observed in some tumor cell lines (Xu et al. [@CR36]), more studies on 3EZ,20Ac-ingenol, which induces decatenation checkpoint through G2/M arrest by catalytic topo inhibitor and downregulates p-Akt, may provide useful information for developing anti-cancer agents.
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